CASR and hypercalcemia disease: Oral cinacalcet may be an efficacious therapy for malignancy-related hypercalcemia to elevate 1,25-dihydroxyvitamin D. Furthermore, it is hypothesized that this effect is primarily mediated by the interaction of cinacalcet with CaSR in the intestine, with lesser effects on the bones and kidneys.